Kidney International Reports最新文献

{"title":"Addressing the Multisystemic Impacts of Nephropathic Cystinosis in an Adult","authors":"Jeanine R. Jarnes , Rebekah S. Palmer , Chester B. Whitley","doi":"10.1016/j.ekir.2024.10.039","DOIUrl":"10.1016/j.ekir.2024.10.039","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages S789-S793"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients","authors":"Lucie Maigret ,&nbsp;Lucile Basle ,&nbsp;Valérie Chatelet ,&nbsp;Laure Ecotiere ,&nbsp;Peggy Perrin ,&nbsp;Léonard Golbin ,&nbsp;Dominique Bertrand ,&nbsp;Dany Anglicheau ,&nbsp;Coralie Poulain ,&nbsp;Cyril Garrouste ,&nbsp;Clément Danthu ,&nbsp;Charlotte Boud'hors ,&nbsp;Yannick Le Meur ,&nbsp;Manon Dekeyser ,&nbsp;Fabien Duthe ,&nbsp;Bénédicte Sautenet ,&nbsp;Pierre-Guillaume Deliège ,&nbsp;Philippe Gatault","doi":"10.1016/j.ekir.2024.11.033","DOIUrl":"10.1016/j.ekir.2024.11.033","url":null,"abstract":"<div><h3>Introduction</h3><div>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular prognosis in patients with chronic kidney disease (CKD), diabetes, and heart failure; and slow the decline of kidney dysfunction in patients with albuminuria. Although safety and efficacy of SGLT2i have not been investigated in kidney transplant recipients (KTRs), their marketing authorization leaves the possibility of their use in these patients in France.</div></div><div><h3>Methods</h3><div>This was a prospective multicenter real-life study including all consecutive KTRs treated with SGLT2i.</div></div><div><h3>Results</h3><div>We identified 347 KTRs treated with SGLT2i (97% with dapagliflozin), with an initiation of treatment most often beyond the first year after transplantation (87%). Importantly, 226 (65.1%) were diabetic and 245 (70.6%) were treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs). We found a low incidence of urinary tract infections (UTIs) (6.6%) and genital mycosis (0.6%), without any serious adverse event. Overall, SGLT2i were stopped in 54 patients (15.6%). The causes of SGLT2i discontinuations were very diverse. The main causes were graft dysfunction (32%), intercurrent infections (17%), urinary infections (11%), and digestive symptoms (9%). KTRs with a low estimated glomerular filtration rate (eGFR), especially those with eGFR &lt; 30 ml/min per 1.73 m², presented with the highest incidence of SGLT2i discontinuation (<em>P</em> = 0.003). SGLT2i were associated with a reduction in proteinuria, found in both diabetic and nondiabetic KTRs. In addition, they had an antihypertensive effect restricted to uncontrolled-hypertensive patients.</div></div><div><h3>Conclusion</h3><div>SGLT2i have been used in KTRs since their authorization in France. They were discontinued more frequently in patients with impaired graft function; however, the expected side effects were infrequent and not life-threatening. The short-term antiproteinuric and antihypertensive effects are promising.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 816-827"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Scoping Review of Socioeconomic Burden and Associated Psychosocial Impact in Patients With Rare Kidney Diseases and Their Caregivers","authors":"Anna Palagyi ,&nbsp;Agnivo Sengupta ,&nbsp;Monica Moorthy ,&nbsp;Charu Malik ,&nbsp;Jonathan Barratt ,&nbsp;Olivier Devuyst ,&nbsp;Ifeoma I. Ulasi ,&nbsp;Daniel P. Gale ,&nbsp;Siyuan Wang ,&nbsp;Blake Angell ,&nbsp;Vivekanand Jha ,&nbsp;Stephen Jan","doi":"10.1016/j.ekir.2024.12.005","DOIUrl":"10.1016/j.ekir.2024.12.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Rare kidney diseases constitute a significant public health challenge but have attracted limited research investment. The evidence about the socioeconomic burden of rare kidney diseases has not been systematically examined. Such evidence is critical for generating the advocacy and awareness necessary to impel scientific and policy investment in targeted care in health systems worldwide. We aimed to evaluate the socioeconomic burden borne by patients with rare kidney diseases, their families, and caregivers, and the related psychosocial impact.</div></div><div><h3>Methods</h3><div>We undertook a systemic scoping review of the recent evidence of the socioeconomic and psychosocial burden of rare kidney diseases, to identify gaps in the understanding of this burden across contexts and factors influencing them. Three databases and the grey literature were searched for relevant studies published in the 10 years before April 30, 2023.</div></div><div><h3>Results</h3><div>Fifty-three articles met the inclusion criteria; one-quarter of these articles included rare disease cohorts in which the kidney was the primary organ affected, and 91% of studies were conducted in high-income countries. Evidence of substantial life-long socioeconomic burden emerged across the following 4 main categories: education (<em>n</em> = 17 articles [32%]), work and employment (<em>n</em> = 40 [75%] articles), psychosocial and emotional impact (<em>n</em> = 17 [32%]), and out-of-pocket expenses (<em>n</em> = 15 [28%]).</div></div><div><h3>Conclusion</h3><div>Significant gaps in our understanding of the socioeconomic burden remain, particularly in lower-resource health systems, among traditionally marginalized populations, and for rare diseases for which kidney is the primary affected organ. Further exploration of socioeconomic burden within these populations is vital to inform effectively targeted investment in advocacy and health care innovation for affected individuals.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 838-854"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Genetic Testing in Nephrology: Options and Decision-Making Strategies","authors":"Emily Groopman ,&nbsp;Hila Milo Rasouly","doi":"10.1016/j.ekir.2024.12.020","DOIUrl":"10.1016/j.ekir.2024.12.020","url":null,"abstract":"<div><div>Technological advances such as next-generation sequencing (NGS) have enabled high-throughput assessment of the human genome, supporting the usage of genetic testing as a first-line tool across clinical medicine. Although individually rare, genetic causes account for end-stage renal disease in 10% to 15% of adults and 70% of children, and in many of these individuals, genetic testing can identify a specific etiology and meaningfully impact management. However, with numerous options for genetic testing available, nephrologists may feel uncomfortable integrating genetics into their clinical practice. Here, we aim to demystify the process of genetic test selection and highlight the opportunities for interdisciplinary collaboration between nephrologists and genetics professionals, thereby supporting precision medicine for patients with kidney disease. We first detail the various clinical genetic testing modalities, highlighting their technical advantages and limitations, and then discuss indications for their usage. Next, we provide a generalized workflow for genetic test selection among individuals with kidney disease and illustrate how this workflow can be applied to genetic test selection across diverse clinical contexts. We then discuss key areas related to the usage of genetic testing in clinical nephrology that merit further research and approaches to investigate them.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 673-695"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"If I Needed Dialysis: Therapy Choices of Indian Nephrology Health Care Professionals","authors":"Mythri Shankar ,&nbsp;Jyoti Baharani ,&nbsp;Krithika Mohan ,&nbsp;Arvind Conjeevaram ,&nbsp;Rizwan Hamer ,&nbsp;Urmila Anandh","doi":"10.1016/j.ekir.2025.01.004","DOIUrl":"10.1016/j.ekir.2025.01.004","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 970-972"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics and Side Effects of Δ9-Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD","authors":"Marie Bach Sønderskov ,&nbsp;Dinah Sherzad Khatir ,&nbsp;Krista Dybtved Kjærgaard ,&nbsp;Jørgen Bo Hasselstrøm ,&nbsp;Lambert Kristiansen Sørensen ,&nbsp;Eva Aggerholm Sædder ,&nbsp;Charlotte Uggerhøj Andersen","doi":"10.1016/j.ekir.2024.12.030","DOIUrl":"10.1016/j.ekir.2024.12.030","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic kidney disease (CKD) affects approximately 10% of the global population and is associated with a large symptom burden. Medicinal cannabis is advised against in patients with severe CKD. However, pharmacokinetic and pharmacodynamic knowledge regarding their use in patients with CKD is lacking.</div></div><div><h3>Methods</h3><div>We aimed to investigate the pharmacokinetics and side effects of a single dose of Sativex, corresponding to 5.4 mg Δ⁹-tetrahydrocannabinol (THC) and 5 mg cannabidiol (CBD), in patients with CKD stages 4 and 5 compared with healthy volunteers (controls). The study was a nonrandomized and unblinded clinical study.</div></div><div><h3>Results</h3><div>Twenty controls and 29 patients with CKD completed the study. The area under the curve (AUC) for THC (median [interquartile range]) was 2.76 (1.77–3.48), 4.16 (3.35–5.28), and 4.31 (3.16–5.42) h × ng/ml for controls, and for patients with CKD stages 4 and 5, respectively, with significant differences between patients with CKD and controls. AUC for CBD and metabolites, and other pharmacokinetic parameters, such as maximum concentration (<em>C</em>_max) and excretion of metabolites in urine were also significantly different between patients with CKD and controls. After 1.5 hours, numeric rating scale (NRS) scores for dizziness were significantly higher for each CKD group compared with controls (mean NRSscores: 0.7 and 1.5 vs. 0.1).</div></div><div><h3>Conclusion</h3><div>Total exposure to THC, CBD, and metabolites was higher in patients with CKD stages 4 and 5 compared with controls, and side effects may be more pronounced; however, the intersubject variability was high. If cannabis products are administered to patients with severe CKD, caution is needed.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 707-719"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitioning Care in Nephropathic Cystinosis: Overcoming Challenges in Young Adults","authors":"Cybele Ghossein ,&nbsp;Laura Nishi","doi":"10.1016/j.ekir.2024.10.036","DOIUrl":"10.1016/j.ekir.2024.10.036","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages S784-S788"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APOL1 Genotype and HIV Infection: 20-Year Outcomes for CKD, Cardiovascular Disease, and Hypertension","authors":"Katherine K. Tassiopoulos ,&nbsp;Kunling Wu ,&nbsp;Zhenzhen Wu ,&nbsp;Edgar T. Overton ,&nbsp;Frank J. Palella ,&nbsp;Christina Wyatt ,&nbsp;Robert C. Kalayjian ,&nbsp;Leslie A. Bruggeman","doi":"10.1016/j.ekir.2024.12.022","DOIUrl":"10.1016/j.ekir.2024.12.022","url":null,"abstract":"<div><h3>Introduction</h3><div><em>APOL1</em> variant alleles substantially increase the risk for chronic kidney disease (CKD) in Black individuals, especially in the setting of HIV infection; however, their impact on hypertension and cardiovascular disease (CVD) is unclear.</div></div><div><h3>Methods</h3><div>Black persons with HIV (<em>n =</em> 1194) followed in the AIDS Clinical Trials Group (ACTG) observational studies A5001 and A5322 were genotyped for <em>APOL1</em> risk alleles. Cox proportional hazard models were used to assess associations between <em>APOL1</em> genotype and incident CKD, CVD, and hypertension, and linear mixed effects models were used to examine associations with longitudinal estimated glomerular filtration rate (eGFR) and proteinuria. Plasma HIV-1 viral suppression was evaluated as an effect modifier.</div></div><div><h3>Results</h3><div><em>APOL1</em> genotype was associated with CKD, but not with hypertension or CVD, although CVD events were infrequent in this relatively young cohort. Annual rates of eGFR decline and proteinuria were greater among persons with <em>APOL1</em> risk alleles, including a detrimental effect of 1 <em>APOL1</em> risk allele, which only became evident in the second decade of follow-up. Sustained HIV-1 viral suppression did not alter the association between incident CKD and <em>APOL1</em> genotype; however, it was associated with a slower rate of eGFR decline and less proteinuria in participants with at least 1 <em>APOL1</em> risk allele, including individuals with eGFRs above the CKD threshold throughout follow-up.</div></div><div><h3>Conclusion</h3><div>Among treated persons with HIV, <em>APOL1</em> risk alleles were associated with CKD and eGFR decline, including an effect of 1 <em>APOL1</em> risk allele which took longer to manifest and was greater in individuals who did not achieve sustained viral suppression. Conversely, no association between <em>APOL1</em> risk alleles and incident hypertension or CVD was detected.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 855-865"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it Time to Expand the Use of SGLT2 Inhibitors in Kidney Transplant Recipients?","authors":"Kajaree Giri ,&nbsp;Geoffrey K. Dube","doi":"10.1016/j.ekir.2025.01.007","DOIUrl":"10.1016/j.ekir.2025.01.007","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 660-662"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The International Society of Nephrology Collaborative Quality Framework to Support Safe and Effective Dialysis Provision in Resource-Challenged Settings","authors":"Simon Davies ,&nbsp;Saraladevi Naicker ,&nbsp;Adrian Liew ,&nbsp;Tushar Vachharajani ,&nbsp;Roberto Pecoits-Filho ,&nbsp;Vivekanand Jha ,&nbsp;Fredric Finkelstein ,&nbsp;David C.H. Harris","doi":"10.1016/j.ekir.2024.11.1366","DOIUrl":"10.1016/j.ekir.2024.11.1366","url":null,"abstract":"<div><div>Global underprovision of affordable dialysis results in inequitable access to safe and effective treatment. The need for a dialysis quality framework that would set minimum standards for safe and effective treatment, was identified as a key priority for the International Society of Nephrology (ISN) Kidney Failure Strategy. In addition, this framework, which was developed through collaboration and iterative review to ensure external validity, links these standards to resource requirements and suggested reporting tools. The framework includes elements that are designed to minimize catastrophic health care expenditure, by mandating transparent individualized affordable dialysis planning and encourages continuous quality improvement by including a tiered approach to standards. Although a set of minimum mandatory standards is included with a strong focus on patient safety, this is not intended as a goal for all, but to support the incremental development of dialysis in the most challenging resource settings. Providers and funders are expected to engage with the framework at a level commensurate with their resources, clearly identifying the area where lack of resource is leading to suboptimal quality. In this way, the framework empowers policy makers, health care commissioners, and patient groups to work with providers to ensure quality and meet demand.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 663-672"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}